Dr. Goriounova successfully defended her thesis, 鈥淓LD607 is a novel, specific Orai1 inhibitor,鈥� on May 10.
Her PhD Advisor was Dr. Robert Tarran.
Dr. Goriounova will be starting a position at Priovant Therapeutics as an Early Development Clinical Pharmacology Fellow. Priovant is a clinical stage company developing the anti-inflammatory Brepocitinib for orphan diseases.
Publications
Goriounova AS, Gilmore RC, Wrennall JA, Tarran R. J Cyst Fibros. 2023 Jan;22(1):161-171. Epub 2022 Aug 10. PMID: 35961837; PMCID: PMC9982747.
Wu T, Goriounova AS, Worthington EN, Wrennall JA, Ghosh A, Ahmad S, Flori Sassano M, Tarran R. 聽Physiol Rep. 2022 May;10(10):e15306. PMID: 35581745; PMCID:
Wrennall JA, Ahmad S, Worthington EN, Wu T, Goriounova AS, Voeller AS, Stewart IE, Ghosh A, Krajewski K, Tilley SL, Hickey AJ, Sassano MF, Tarran R. Am J Respir Cell Mol Biol. 2022 Mar;66(3):271-282. . PMID: 34807800; PMCID:
Dr. Goriounova is starting a new position at Priovant Therapeutics as an Early Development Clinical Pharmacology Fellow. Priovant is a clinical stage company developing the anti-inflammatory Brepocitinib for orphan diseases.
UPDATE!
Below are pics from Sasha’s White Coat Ceremony after her PhD defense presentation when Henrik Dohlman presented her with her PHCO White Coat. (click for larger view)
We wish you all the best, Sasha!